Updates are available Correction dated 2020-09-02
Click to view Correction: https://doi.org/10.1038/s41590-020-0794-2
-
Authors
Winkler, Emma S.
Bailey, Adam L.
Kafai, Natasha M.
Nair, Sharmila
McCune, Broc T.
Yu, Jinsheng http://orcid.org/0000-0003-3377-4304
Fox, Julie M. http://orcid.org/0000-0003-0567-738X
Chen, Rita E.
Earnest, James T.
Keeler, Shamus P. http://orcid.org/0000-0002-1301-0852
Ritter, Jon H.
Kang, Liang-I
Dort, Sarah
Robichaud, Annette
Head, Richard
Holtzman, Michael J. http://orcid.org/0000-0001-8750-3716
Diamond, Michael S. http://orcid.org/0000-0002-8791-3165
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00062, R01 AI127828, R01 AI130591, R35 HL145242, F32 AI138392)
United States Department of Defense | Defense Advanced Research Projects Agency (HR001117S0019)
- License Information
-
More Information
Article History
Received: 9 July 2020
Accepted: 7 August 2020
First Online: 24 August 2020
Change Date: 2 September 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: M.S.D. is a consultant for InBios, Vir Biotechnology and NGM Biopharmaceuticals and is on the scientific advisory board of Moderna. The Diamond laboratory has received funding under sponsored research agreements from Moderna, Vir Biotechnology and Emergent BioSolutions. S.D. and A.R. are employed by SCIREQ—a commercial entity with commercial interest in a subject area related to the content of this article. SCIREQ is an emka TECHNOLOGIES company. M.J.H. is a member of the Data and Safety Monitoring Board for AstroZeneca and founder of NuPeak Therapeutics. The other authors declare no competing interests.
Free to read: This content has been made available to all.
